Zacks Small-Cap Research (Zacks SCR) sees MediciNova, which develops treatments for amyotrophic lateral sclerosis (ALS) and pulmonary fibrosis, as significantly undervalued. In a recent Zacks SCR note, the stock’s fair value is estimated at $10 per share — five times its current price. MediciNova is set to receive compensation from pharmaceutical…